Antares Pharma Inc (NASDAQ:ATRS) saw a significant increase in short interest in the month of September. As of September 28th, there was short interest totalling 9,429,404 shares, an increase of 38.1% from the September 14th total of 6,826,443 shares. Currently, 6.6% of the company’s stock are short sold. Based on an average daily trading volume, of 1,525,611 shares, the short-interest ratio is currently 6.2 days.
A number of analysts have weighed in on ATRS shares. ValuEngine upgraded Antares Pharma from a “hold” rating to a “buy” rating in a report on Thursday, July 5th. Raymond James upped their target price on Antares Pharma from $3.85 to $5.25 and gave the stock a “strong-buy” rating in a report on Tuesday, October 2nd. BidaskClub lowered Antares Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 23rd. Jefferies Financial Group upped their target price on Antares Pharma to $7.00 and gave the stock a “buy” rating in a report on Tuesday, October 2nd. Finally, HC Wainwright set a $5.00 target price on Antares Pharma and gave the stock a “buy” rating in a report on Monday, October 1st. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $5.31.
Shares of ATRS opened at $3.36 on Friday. Antares Pharma has a 12 month low of $1.58 and a 12 month high of $3.93. The company has a quick ratio of 1.89, a current ratio of 2.33 and a debt-to-equity ratio of 1.01. The firm has a market cap of $528.99 million, a PE ratio of -30.55 and a beta of 0.39.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Antares Pharma had a negative net margin of 35.53% and a negative return on equity of 64.96%. The business had revenue of $14.16 million for the quarter, compared to analysts’ expectations of $13.70 million. Analysts forecast that Antares Pharma will post -0.1 earnings per share for the current year.
In other Antares Pharma news, Director Jacques Gonella sold 400,000 shares of the company’s stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $3.79, for a total transaction of $1,516,000.00. Following the completion of the sale, the director now owns 9,585,848 shares in the company, valued at $36,330,363.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Robert F. Apple sold 43,000 shares of the company’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $3.75, for a total value of $161,250.00. Following the sale, the chief executive officer now owns 1,573,562 shares of the company’s stock, valued at approximately $5,900,857.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 743,000 shares of company stock valued at $2,604,250. 12.20% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of ATRS. Wells Fargo & Company MN lifted its holdings in shares of Antares Pharma by 21.5% during the 1st quarter. Wells Fargo & Company MN now owns 1,933,469 shares of the specialty pharmaceutical company’s stock valued at $4,253,000 after purchasing an additional 342,062 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Antares Pharma by 17.3% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 711,562 shares of the specialty pharmaceutical company’s stock valued at $1,566,000 after purchasing an additional 104,733 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Antares Pharma by 533.6% during the 1st quarter. JPMorgan Chase & Co. now owns 448,634 shares of the specialty pharmaceutical company’s stock valued at $987,000 after purchasing an additional 377,824 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Antares Pharma during the 1st quarter valued at $1,959,000. Finally, MetLife Investment Advisors LLC lifted its holdings in shares of Antares Pharma by 281.1% during the 1st quarter. MetLife Investment Advisors LLC now owns 71,731 shares of the specialty pharmaceutical company’s stock valued at $158,000 after purchasing an additional 52,911 shares during the last quarter. Hedge funds and other institutional investors own 38.92% of the company’s stock.
About Antares Pharma
Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Featured Article: What do I need to know about analyst ratings?
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.